Classification of patients according to pathological and molecular diagnosis
| Pathological diagnosis . | BL (n = 36) . | DLBCL (n = 79) . | PMBL (n = 12) . | HGL-UC (n = 6) . | TCR-DLBCL (n = 5) . | ||
|---|---|---|---|---|---|---|---|
| Pediatric (n = 22) . | Adult (n = 14) . | Pediatric (n = 12) . | Adult (n = 67) . | ||||
| Age at diagnosis median (range) | 10 (2-20) | 67 (32-82) | 14 (3-18) | 66 (21-85) | 27 (15-73) | 53 (43-78) | 66 (59-87) |
| Gender | |||||||
| Female | 4 | 6 | 2 | 33 | 9 | 4 | 2 |
| Male | 18 | 8 | 10 | 34 | 3 | 2 | 3 |
| Molecular diagnosis* | |||||||
| mBL | 18 | 11 | 2 | 3 | — | 3 | — |
| mDLBCL | 4 | 2 | 8 | 62 | 12 | 3 | 5 |
| UC† | — | 1 | 2 | 2 | — | — | — |
| Pathological diagnosis . | BL (n = 36) . | DLBCL (n = 79) . | PMBL (n = 12) . | HGL-UC (n = 6) . | TCR-DLBCL (n = 5) . | ||
|---|---|---|---|---|---|---|---|
| Pediatric (n = 22) . | Adult (n = 14) . | Pediatric (n = 12) . | Adult (n = 67) . | ||||
| Age at diagnosis median (range) | 10 (2-20) | 67 (32-82) | 14 (3-18) | 66 (21-85) | 27 (15-73) | 53 (43-78) | 66 (59-87) |
| Gender | |||||||
| Female | 4 | 6 | 2 | 33 | 9 | 4 | 2 |
| Male | 18 | 8 | 10 | 34 | 3 | 2 | 3 |
| Molecular diagnosis* | |||||||
| mBL | 18 | 11 | 2 | 3 | — | 3 | — |
| mDLBCL | 4 | 2 | 8 | 62 | 12 | 3 | 5 |
| UC† | — | 1 | 2 | 2 | — | — | — |
HGL, high-grade lymphoma; m, molecular; TCR, T-cell-rich.
Molecular diagnosis is the Bayesian classification of cases using the Burkitt Lymphoma Gene Signature derived from Dave et al.8 Cases in bold font had a molecular classification that was discrepant with the pathological diagnosis.
UC indicates unclassifiable cases with a diagnostic probability of <90% by Bayesian classification.